Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjögren's syndrome.

Chen YT, Nikulina K, Lazarev S, Bahrami AF, Noble LB, Gallup M, McNamara NA.

Am J Pathol. 2010 Sep;177(3):1333-43. doi: 10.2353/ajpath.2010.100227. Epub 2010 Aug 9.

2.

Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjögren's syndrome.

Chen YT, Lazarev S, Bahrami AF, Noble LB, Chen FY, Zhou D, Gallup M, Yadav M, McNamara NA.

Lab Invest. 2012 Apr;92(4):556-70. doi: 10.1038/labinvest.2011.189. Epub 2012 Jan 9.

3.

Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye.

Chen YT, Li S, Nikulina K, Porco T, Gallup M, McNamara N.

Mol Vis. 2009;15:563-76. Epub 2009 Mar 23.

4.

Small proline-rich protein 1B (SPRR1B) is a biomarker for squamous metaplasia in dry eye disease.

Li S, Nikulina K, DeVoss J, Wu AJ, Strauss EC, Anderson MS, McNamara NA.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):34-41. doi: 10.1167/iovs.07-0685.

5.

Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.

Vijmasi T, Chen FY, Chen YT, Gallup M, McNamara N.

Mol Vis. 2013 Sep 19;19:1957-65. eCollection 2013.

6.

Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye.

Zhou D, Chen YT, Chen F, Gallup M, Vijmasi T, Bahrami AF, Noble LB, van Rooijen N, McNamara NA.

Am J Pathol. 2012 Sep;181(3):753-60. doi: 10.1016/j.ajpath.2012.05.014. Epub 2012 Jul 4.

7.

Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndrome.

McNamara NA, Gallup M, Porco TC.

Invest Ophthalmol Vis Sci. 2014 Sep 16;55(11):7079-84. doi: 10.1167/iovs.14-14828.

8.

Pathological Analysis of Ocular Lesions in a Murine Model of Sjögren's Syndrome.

Ushio A, Arakaki R, Eguchi H, Hotta F, Yamada A, Kudo Y, Ishimaru N.

Int J Mol Sci. 2017 Jun 6;18(6). pii: E1209. doi: 10.3390/ijms18061209.

9.

Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.

Diebold Y, Chen LL, Tepavcevic V, Ferdman D, Hodges RR, Dartt DA.

Exp Eye Res. 2007 Mar;84(3):500-12. Epub 2007 Jan 17.

PMID:
17208228
10.

Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation.

Pflugfelder SC, Tseng SC, Yoshino K, Monroy D, Felix C, Reis BL.

Ophthalmology. 1997 Feb;104(2):223-35.

PMID:
9052626
11.

Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.

Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S.

Am J Pathol. 2009 Sep;175(3):1136-47. doi: 10.2353/ajpath.2009.081058. Epub 2009 Aug 21.

12.

Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.

Contreras-Ruiz L, Mir FA, Turpie B, Krauss AH, Masli S.

Exp Eye Res. 2016 Feb;143:1-8. doi: 10.1016/j.exer.2015.10.008. Epub 2015 Oct 14.

PMID:
26463157
13.

Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.

Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC.

Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3493-504.

PMID:
8056525
14.

Thrombospondin-derived peptide attenuates Sjögren's syndrome-associated ocular surface inflammation in mice.

Contreras Ruiz L, Mir FA, Turpie B, Masli S.

Clin Exp Immunol. 2017 Apr;188(1):86-95. doi: 10.1111/cei.12919. Epub 2017 Jan 31.

PMID:
28033649
15.

IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.

Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, Ambrus JL Jr.

Clin Immunol. 2009 Mar;130(3):304-12. doi: 10.1016/j.clim.2008.10.006. Epub 2008 Nov 26.

PMID:
19038581
16.

Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren's syndrome.

Chen FY, Lee A, Ge S, Nathan S, Knox SM, McNamara NA.

PLoS One. 2017 Sep 19;12(9):e0184916. doi: 10.1371/journal.pone.0184916. eCollection 2017.

17.

Alterations of ocular surface gene expression in Sjögren's syndrome.

Jones DT, Monroy D, Ji Z, Pflugfelder SC.

Adv Exp Med Biol. 1998;438:533-6.

PMID:
9634933
18.

ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.

Gao J, Morgan G, Tieu D, Schwalb TA, Luo JY, Wheeler LA, Stern ME.

Exp Eye Res. 2004 Apr;78(4):823-35.

PMID:
15037117
19.

Pax6 downregulation mediates abnormal lineage commitment of the ocular surface epithelium in aqueous-deficient dry eye disease.

Chen YT, Chen FY, Vijmasi T, Stephens DN, Gallup M, McNamara NA.

PLoS One. 2013 Oct 15;8(10):e77286. doi: 10.1371/journal.pone.0077286. eCollection 2013.

20.

Altered balance of interleukin-13/interferon-gamma contributes to lacrimal gland destruction and secretory dysfunction in CD25 knockout model of Sjögren's syndrome.

Bian F, Barbosa FL, Corrales RM, Pelegrino FS, Volpe EA, Pflugfelder SC, de Paiva CS.

Arthritis Res Ther. 2015 Mar 10;17:53. doi: 10.1186/s13075-015-0582-9.

Supplemental Content

Support Center